[go: up one dir, main page]

MX2009003834A - Derivados de pirrolidina como inhibidores de iap. - Google Patents

Derivados de pirrolidina como inhibidores de iap.

Info

Publication number
MX2009003834A
MX2009003834A MX2009003834A MX2009003834A MX2009003834A MX 2009003834 A MX2009003834 A MX 2009003834A MX 2009003834 A MX2009003834 A MX 2009003834A MX 2009003834 A MX2009003834 A MX 2009003834A MX 2009003834 A MX2009003834 A MX 2009003834A
Authority
MX
Mexico
Prior art keywords
pyrrolydine
derivatives
iap inhibitors
iap
inhibitors
Prior art date
Application number
MX2009003834A
Other languages
English (en)
Inventor
Leigh Zawel
Christopher Straub
Zhuoliang Chen
Mark G Charest
Feng He
Miao Dai
Huangshu Lei
Run-Ming David Wang
Christine Hiu-Tung Chen
Ming Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009003834A publication Critical patent/MX2009003834A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a novedosos compuestos inhibidores de IAP de la fórmula (I): (ver fórmula (I)).
MX2009003834A 2006-10-12 2007-10-10 Derivados de pirrolidina como inhibidores de iap. MX2009003834A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82923406P 2006-10-12 2006-10-12
PCT/US2007/080875 WO2008045905A1 (en) 2006-10-12 2007-10-10 Pyrrolydine derivatives as iap inhibitors

Publications (1)

Publication Number Publication Date
MX2009003834A true MX2009003834A (es) 2009-04-22

Family

ID=38984426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003834A MX2009003834A (es) 2006-10-12 2007-10-10 Derivados de pirrolidina como inhibidores de iap.

Country Status (11)

Country Link
US (1) US8044209B2 (es)
EP (1) EP2102229B1 (es)
JP (1) JP5190062B2 (es)
KR (1) KR20090065548A (es)
CN (1) CN101595121A (es)
AU (1) AU2007307763A1 (es)
BR (1) BRPI0719221A2 (es)
CA (1) CA2666112A1 (es)
MX (1) MX2009003834A (es)
RU (1) RU2009117701A (es)
WO (1) WO2008045905A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005022936D1 (de) 2004-12-20 2010-09-23 Genentech Inc Pyrrolidine als inhibitoren von iap
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
EP1973899A4 (en) 2005-12-19 2010-10-20 Genentech Inc HEMMER OF IAP
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
PE20110218A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CA2671607A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
AR066348A1 (es) * 2007-04-30 2009-08-12 Genentech Inc Inhibidores de las iap
ES2882855T3 (es) * 2008-05-16 2021-12-02 Dana Farber Cancer Inst Inc Inmunomodulación por inhibidores de IAP
CN102171209A (zh) 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
KR20110092266A (ko) 2008-08-04 2011-08-17 씨에이치디아이 파운데이션, 인코포레이티드 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법
AU2009282978A1 (en) * 2008-08-16 2010-02-25 Genentech, Inc. Azaindole inhibitors of IAP
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
WO2012030160A2 (en) * 2010-08-31 2012-03-08 Hanmi Holdings Co., Ltd. Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EP2651917A1 (en) * 2010-12-13 2013-10-23 Novartis AG Dimeric iap inhibitors
JP2014094886A (ja) * 2011-02-28 2014-05-22 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
EP2736337A4 (en) * 2011-07-28 2014-12-17 Chdi Foundation Inc CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EP3243515B1 (en) 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
NO2755614T3 (es) * 2012-01-03 2018-03-31
JP6321020B2 (ja) * 2012-10-19 2018-05-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 二環式複素環化合物およびそれらの治療での使用
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
JP6324976B2 (ja) * 2012-10-19 2018-05-16 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 二環式複素環化合物およびそれらの治療での使用
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
DK3083616T3 (da) 2013-12-20 2021-08-30 Astex Therapeutics Ltd Bicykliske heterocykliske forbindelser og disses anvendelser i terapi
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
EA034528B1 (ru) 2014-07-17 2020-02-17 Сиэйчдиай Фаундэйшн, Инк. Способ лечения нарушений, связанных с вич
KR20170004160A (ko) * 2015-07-01 2017-01-11 엘지전자 주식회사 이동단말기 및 그 제어방법
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CN114685602A (zh) * 2017-11-13 2022-07-01 正大天晴药业集团股份有限公司 用作iap抑制剂的smac模拟物及其用途
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
US20220175917A1 (en) * 2019-03-07 2022-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination of iap inhibitor and immune checkpoint inhibitor
DK3967702T3 (da) * 2019-05-10 2024-04-15 Chia Tai Tianqing Pharmaceutical Group Co Ltd Krystallisering af smac-mimic anvendt som iap-inhibitor og fremgangsmåde til fremstilling deraf
JP7764027B2 (ja) 2019-07-31 2025-11-05 ファイメクス株式会社 複素環化合物
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002407A0 (en) 2000-05-23 2002-03-31 Vertex Pharma Caspase inhibitors and uses thereof.
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) * 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
BRPI0509721A (pt) * 2004-04-07 2007-09-25 Novartis Ag inibidores de iap
NZ588799A (en) * 2004-07-02 2012-06-29 Genentech Inc Inhibitors of iap
DE602005022936D1 (de) 2004-12-20 2010-09-23 Genentech Inc Pyrrolidine als inhibitoren von iap
EP1973899A4 (en) * 2005-12-19 2010-10-20 Genentech Inc HEMMER OF IAP

Also Published As

Publication number Publication date
EP2102229A1 (en) 2009-09-23
BRPI0719221A2 (pt) 2014-03-18
JP5190062B2 (ja) 2013-04-24
WO2008045905A1 (en) 2008-04-17
CA2666112A1 (en) 2008-04-17
RU2009117701A (ru) 2010-11-20
US8044209B2 (en) 2011-10-25
EP2102229B1 (en) 2014-03-26
AU2007307763A1 (en) 2008-04-17
KR20090065548A (ko) 2009-06-22
CN101595121A (zh) 2009-12-02
US20110015232A1 (en) 2011-01-20
JP2010506847A (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
SG171593A1 (en) Inhibitors of c-fms kinase
MX2009005934A (es) Compuestos organicos.
MY150596A (en) Hsp90 inhibitors
WO2006133147A3 (en) Organic compounds
MX2009000884A (es) Derivados de piridizinona.
JO2947B1 (en) Compounds corresponding to cyclopamine
ECSP066893A (es) Inhibidores de proteínas de apoptosis (iap)
MY150460A (en) Smac peptidomimetics useful as iap inhibitors
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2007105058A3 (en) Pyrazole compounds
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
WO2007085895A3 (en) Fap inhibitors
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MY150542A (en) Cmet inhibitors
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
MX2008000017A (es) Derivados de isoquinolina como inhibidores de rho-cinasa.
MY150778A (en) Fused heterocyclic compound
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium